(c) In vitro
| Article | Study type | Administered dose | Relevance |
|---|---|---|---|
| [63] |
In vitro: MCF-7 cells T47D cells MDA-MB-231 cells |
3–10 μM | Resveratrol exhibits variable degrees of estrogen receptor agonism in different test systems |
|
| |||
| [89] |
In vitro: DU-145, PC-3, and JCA-1 human prostate cancer cells |
25 μM | Resveratrol negatively modulates prostate cancer cell growth |
|
| |||
| [90] |
In vitro: HL-60 cells Hepa LcLc7 cells |
11, 18, 21, 27 μM | Resveratrol is a potential cancer chemopreventive agent |
|
| |||
| [91] |
In vitro: MCF7 cells |
10 μM | Resveratrol blocks the aryl hydrocarbon receptor and has beneficial effects against some types of tumors |
|
| |||
| [92] |
In vitro: MCF7 cells |
10, 50, 100, 150 μM | The anticancer effect of resveratrol is via BCL-2 and NFκB |
|
| |||
| [93] |
In vitro: human lymphoblast cells |
2.5, 5, 10, 20, 40 μM | The anticancer effect of resveratrol is via p53 |
|
| |||
| [94] |
In vitro: L1210-R2 murine lymphoblastic leukemia cells K-562 human myelogenous leukemia cells P-815 murine mastocytoma cells |
0.1–1000 μM | The anticancer effect of resveratrol is via inhibiting ribonuclease reductase |
|
| |||
| [95] |
In vitro: murine 3T6 fibroblast |
0.3–30 μM | Reactive oxygen species and arachidonic acid might be involved in the control of 3T6 fibroblast growth by resveratrol |
|
| |||
| [98] |
In vitro: human platelets |
0.1, 1.0 and 10.0 μM | trans-Resveratrol is an inhibitor of store-operated Ca2+ channels in human platelets. This accounts for the ability of trans-resveratrol to inhibit platelet aggregation induced by thrombin |
|
| |||
| [104] |
In vitro: Saccharomyces cerevisiae |
0–500 μM | Resveratrol stimulates Sir2, thus increasing DNA stability and extending lifespan |